Achieve Life Sciences' Cytisinicline to Unlock $760 Million Market Opportunity in Smoking Cessation, Morgan Stanley Says

MT Newswires Live

08/13

Achieve Life Sciences' (ACHV) Cytisinicline treatment for smoking cessation in adults will unlock about a $760 million market opportunity for the company, Morgan Stanley said in a Thursday note.

The company plans to resubmit the new drug application for Cytisinicline in Q4, with potential approval from the US Food and Drug Administration in H1 2027, the brokerage noted.

Achieve Life Sciences has developed an improved formulation and simpler treatment schedule for the drug, with its phase 3 study demonstrating "significantly greater" smoking abstinence rates compared with placebo, Morgan Stanley said

The company is also evaluating Cytisinicline in e-cigarette cessation, potentially unlocking an additional $330 million market opportunity, the investment firm added.

Morgan Stanley initiated coverage on Achieve Life Sciences with an overweight rating and a $13 price target.

Price: 7.08, Change: +0.39, Percent Change: +5.81

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2659657761"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2659657761\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2659657761?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 23:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2659657761","market":"hk","top_or_hot":-1,"title":"Achieve Life Sciences' Cytisinicline to Unlock $760 Million Market Opportunity in Smoking Cessation, Morgan Stanley Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ACHV\">Achieve Life</a> Sciences' (ACHV) Cytisinicline treatment for smoking cessation in adults will unlock about a $760 million market opportunity for the company, Morgan Stanley said in a Thursday note.</p><p>The company plans to resubmit the new drug application for Cytisinicline in Q4, with potential approval from the US Food and Drug Administration in H1 2027, the brokerage noted.</p><p>Achieve Life Sciences has developed an improved formulation and simpler treatment schedule for the drug, with its phase 3 study demonstrating \"significantly greater\" smoking abstinence rates compared with placebo, Morgan Stanley said</p><p>The company is also evaluating Cytisinicline in e-cigarette cessation, potentially unlocking an additional $330 million market opportunity, the investment firm added.</p><p>Morgan Stanley initiated coverage on Achieve Life Sciences with an overweight rating and a $13 price target.</p><p>Price: 7.08, Change: +0.39, Percent Change: +5.81</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Achieve Life Sciences' Cytisinicline to Unlock $760 Million Market Opportunity in Smoking Cessation, Morgan Stanley Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAchieve Life Sciences' Cytisinicline to Unlock $760 Million Market Opportunity in Smoking Cessation, Morgan Stanley Says\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-08-13 23:46</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ACHV\">Achieve Life</a> Sciences' (ACHV) Cytisinicline treatment for smoking cessation in adults will unlock about a $760 million market opportunity for the company, Morgan Stanley said in a Thursday note.</p><p>The company plans to resubmit the new drug application for Cytisinicline in Q4, with potential approval from the US Food and Drug Administration in H1 2027, the brokerage noted.</p><p>Achieve Life Sciences has developed an improved formulation and simpler treatment schedule for the drug, with its phase 3 study demonstrating \"significantly greater\" smoking abstinence rates compared with placebo, Morgan Stanley said</p><p>The company is also evaluating Cytisinicline in e-cigarette cessation, potentially unlocking an additional $330 million market opportunity, the investment firm added.</p><p>Morgan Stanley initiated coverage on Achieve Life Sciences with an overweight rating and a $13 price target.</p><p>Price: 7.08, Change: +0.39, Percent Change: +5.81</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACHV","symbol_name":"Achieve Life Sciences, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2659657761","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2659657761","pubTimestamp":1786635970,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Achieve Life Sciences'  Cytisinicline treatment for smoking cessation in adults will unlock about a $760 million market opportunity for the company, Morgan Stanley said in a Thursday note.The company plans to resubmit the new drug application for Cytisinicline in Q4, with potential approval from the US Food and Drug Administration in H1 2027, the brokerage noted.Achieve Life Sciences has developed an improved formulation and simpler treatment schedule for the drug, with its phase 3 study demonstrating \"significantly greater\" smoking abstinence rates compared with placebo, Morgan Stanley saidThe company is also evaluating Cytisinicline in e-cigarette cessation, potentially unlocking an additional $330 million market opportunity, the investment firm added.Morgan Stanley initiated coverage on Achieve Life Sciences with an overweight rating and a $13 price target.Price: 7.08, Change: +0.39, Percent Change: +5.81","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ACHV":"Achieve Life Sciences, Inc.","BK4139":"生物科技"},"translate_title":"摩根士丹利表示，实现 Life Sciences 的 Cytisinicline 将释放 7.6 亿美元的戒烟市场机会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACHV":1},"content_text":"Achieve Life Sciences' (ACHV) Cytisinicline treatment for smoking cessation in adults will unlock about a $760 million market opportunity for the company, Morgan Stanley said in a Thursday note.The company plans to resubmit the new drug application for Cytisinicline in Q4, with potential approval from the US Food and Drug Administration in H1 2027, the brokerage noted.Achieve Life Sciences has developed an improved formulation and simpler treatment schedule for the drug, with its phase 3 study demonstrating \"significantly greater\" smoking abstinence rates compared with placebo, Morgan Stanley saidThe company is also evaluating Cytisinicline in e-cigarette cessation, potentially unlocking an additional $330 million market opportunity, the investment firm added.Morgan Stanley initiated coverage on Achieve Life Sciences with an overweight rating and a $13 price target.Price: 7.08, Change: +0.39, Percent Change: +5.81","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}